Literature DB >> 1881456

Repeated SKF 38393 and nigrostriatal system neuronal responsiveness: functional down-regulation is followed by up-regulation after withdrawal.

M D Kelland1, D K Pitts, A S Freeman, L A Chiodo.   

Abstract

The effects of chronic administration of the D1 dopamine (DA) agonist SKF 38393 on the basal activity and electrophysiological and pharmacological responsiveness of nigrostriatal DA neurons were examined by means of extracellular, single-unit recording techniques. Chronic D1 stimulation failed to alter either the basal activity of DA neurons or the potency of quinpirole to induce inhibition of these cells. However, 28-day SKF 38393 treatment (but not 14-day treatment) eliminated the ability of subsequent (24 h later) acute SKF 38393 to alter the rate-dependent nature of quinpirole-induced inhibition. In contrast, one week after a 28-day SKF 38393 treatment we found that quinpirole-induced inhibition by itself was no longer rate-dependent, an effect which was reversed by acute pretreatment with the D1 antagonist SCH 23390. This latter finding is suggestive of enhanced endogenous D1 tone. Similarly, 28-day SKF 38393 treatment eliminated the effect of subsequent acute SKF 38393 on sciatic nerve stimulation-induced inhibition of nigrostriatal DA neurons, whereas one week after the chronic D1 regimen these cells were highly sensitive to acute D1 enhancement of the response to sciatic nerve stimulation. In order to address the postsynaptic effects of chronic D1 stimulation, the influence of iontophoretically administered SKF 38393 was examined on type I caudate neurons. Again, 28-day SKF 38393 treatment resulted in reduced sensitivity of caudate neurons tested 24 h later, and an enhanced sensitivity was observed one week after the completion of chronic SKF 38393 administration. Thus, chronic SKF 38393 induced functional desensitization of D1 receptors, but one-week withdrawal was followed by sensitization.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1881456     DOI: 10.1007/bf00169545

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  49 in total

1.  Anesthetic influences on the basal activity and pharmacological responsiveness of nigrostriatal dopamine neurons.

Authors:  M D Kelland; L A Chiodo; A S Freeman
Journal:  Synapse       Date:  1990       Impact factor: 2.562

2.  Cytochemical and electrophysiological studies of dopamine in the caudate nucleus.

Authors:  G R Siggins; B J Hoffer; F E Bloom; U Ungerstedt
Journal:  Res Publ Assoc Res Nerv Ment Dis       Date:  1976

3.  D-1/D-2 dopamine receptor interactions in the regulation of extrapyramidal motor function: studies in animal models and parkinsonian patients.

Authors:  P Barone; A R Braun; T N Chase
Journal:  Clin Neuropharmacol       Date:  1986       Impact factor: 1.592

4.  Repeated stimulation of D-1 dopamine receptors increases the circling response to bromocriptine in rats with a 6-OHDA lesion.

Authors:  C Rouillard; P Bédard; P Falardeau; T Di Paolo
Journal:  Eur J Pharmacol       Date:  1988-11-22       Impact factor: 4.432

5.  Micromethods in neuropharmacology: an approach to the study of anesthetics.

Authors:  G C Salmoiraghi; F Weight
Journal:  Anesthesiology       Date:  1967 Jan-Feb       Impact factor: 7.892

6.  Repeated amphetamine: reduced dopamine neuronal responsiveness to apomorphine but not quinpirole.

Authors:  D K Pitts; A S Freeman; M D Kelland; L A Chiodo
Journal:  Eur J Pharmacol       Date:  1989-03-14       Impact factor: 4.432

7.  Time course of the development of the enhanced behavioral and biochemical responses to amphetamine after pretreatment with amphetamine.

Authors:  M G Kolta; P Shreve; V De Souza; N J Uretsky
Journal:  Neuropharmacology       Date:  1985-09       Impact factor: 5.250

8.  Amphetamine-induced excitations predominate in single neostriatal neurons showing motor-related activity.

Authors:  J L Haracz; J T Tschanz; J Greenberg; G V Rebec
Journal:  Brain Res       Date:  1989-06-12       Impact factor: 3.252

9.  The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset.

Authors:  J A Temlett; P N Chong; W H Oertel; P Jenner; C D Marsden
Journal:  Eur J Pharmacol       Date:  1988-11-01       Impact factor: 4.432

10.  The effect of acute and chronic treatment with SCH 23390 on the spontaneous activity of midbrain dopamine neurons.

Authors:  E Esposito; B S Bunney
Journal:  Eur J Pharmacol       Date:  1989-03-14       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.